Switch to:
More From Other Websites
SEC probing Valeant, Ackman's hostile Allergan bid - WSJ Aug 14 2014
Vertex leads S&P 500, King drops on outlook Aug 13 2014
Vertex to end sales of hepatitis C drug Incivek Aug 13 2014
Shares Rise, as Biotech Gains Offset Listless Retail Sales Aug 13 2014
From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate Aug 12 2014
GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
A Healthy Biotech ETF Aug 08 2014
VERTEX PHARMACEUTICALS INC / MA Financials Aug 08 2014
Today's Stocks Driving Success For The Health Care Sector Aug 08 2014
Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics... Aug 08 2014
Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the... Aug 07 2014
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress Aug 06 2014
Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations Jul 31 2014
VERTEX PHARMACEUTICALS INC / MA Files SEC form 10-Q, Quarterly Report Jul 31 2014
4:18 pm Vertex Pharm receives European approval for KALYDECO (ivacaftor) in eight non-G551D gating... Jul 31 2014
Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations Jul 31 2014
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View Jul 30 2014
Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and... Jul 29 2014
Vertex Pharma posts bigger 2Q loss Jul 29 2014
Vertex Pharma posts bigger 2Q loss Jul 29 2014


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide